Draupnir Bio Logo.JPG
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins
17 juil. 2024 07h00 HE | Draupnir Bio
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins MP Healthcare and EIFO join existing investors, Gilde Healthcare...
bio process.jpg
BioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies
17 juil. 2024 05h15 HE | BioProcess360
BioProcess360 Partners announce the launch of a new investment fund to support businesses with the growth of emerging bioprocessing technologies
Flag_logo.jpg
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
16 juil. 2024 09h00 HE | Flag Therapeutics, Inc.
FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
16 juil. 2024 09h00 HE | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals appoints Tamara Dillon as Chief Human Resources Officer
Seyltx.png
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
16 juil. 2024 07h30 HE | Seyltx, Inc.
- Results will be presented at the London International Cough Symposium on July 18, 2024 - Dose dependent cough suppression to >90% in vivo with no effect on basal respiratory rates - Multiple...
ABIVAX_Logo-RGB.png
Abivax Provides Operational and Key Program Update
15 juil. 2024 16h00 HE | Abivax
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
BHIANT Logo.png
Panthera BioSolutions Launches Pharmaceutical Good Manufacturing Practice (GMP) Foundational Training Course with Dallas College to Advance Workforce Talent Pipeline in North Texas
15 juil. 2024 11h57 HE | BHIANT
DALLAS, July 15, 2024 (GLOBE NEWSWIRE) -- The Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) is proud to announce a strategic partnership between Dallas College and Panthera...
KBLB logo.jpg
Kraig Biocraft Laboratories Completes Phase One of its Spider Silk Production Facility Expansion
15 juil. 2024 07h05 HE | Kraig Biocraft Laboratories
Kraig Labs (OTCQB: KBLB) completed the first phase of construction for its production facility expansion to support the Company's third production wave
Tevogen Logo Notified.png
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
11 juil. 2024 12h21 HE | Tevogen Bio Inc
WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
Kane Logo Cropped TransBG.png
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
11 juil. 2024 08h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with...